Objective: It is unclear to what degree acutely violating bioelectrical impedance analysis (BIA) measurement assumptions will alter the predicted percent fat mass (%FM) and whether this differs by sex or body mass index (BMI).Methods: %FM was assessed under control, dehydration, exercise, water, food intake and non-voided bladder conditions with three BIA devices (Tanita: BC-418, TBF-314, & Omron HBF-306CN) for men (n = 23, age: 24.0 ± 5.2 years old) and women (n = 17, age: 22.5 ± 3.4 years old) separately.Results: For all BIA devices, there were no differences in the %FM values between the control and the other conditions in men or women (− 1.9 to 0.4%,p > 0.05). Across the three devices and five conditions, 97% of %FM tests returned values within 5% of control (2 tests), and 86% of tests were within 2% of control despite violating an assumption. The errors were greatest with dehydration and women were more likely to have a %FM difference greater than 2% than men with dehydration using the hand-to-foot device (Tanita TBF-314: 59% versus 9%). There were no differences in %FM between control and the conditions when examined by BMI (overweight/obesity: − 2.8 to 0.1% and normal weight: − 1.7 to 0.5%; BMI*trial,p = 0.99).Conclusion: %FM estimates were similar despite acutely violating the preliminary measurement BIA assumptions across a range of different BMIs. The minor variations in %FM are smaller than what would be expected with day-to-day variability or weight loss intervention but may be larger in women than men.
Introduction: The EXACOS-CV Canada study described and evaluated treatment patterns, healthcare resource utilisation (HCRU), and costs in patients with COPD who experienced a severe cardiovascular (CV) event or death preceded or not preceded by an exacerbation. Methods: This longitudinal, retrospective cohort study included 142 787 individuals with COPD using administrative data from Alberta, Canada. The index event was a first hospitalisation for a CV event or all-cause death during follow-up. COPD-related treatment, HCRU and costs during the 12-month periods before and after the index events were described. Results: From the initial cohort, 43 564 (30.5%) patients with COPD experienced an index event; 15 100 (34.7%) had a COPD exacerbation in the 12 months prior. Patients whose index event was preceded ( versus not preceded) by an exacerbation were dispensed higher amounts of COPD therapies in the 12 months prior (proportion of dual therapy: 36.9% versus 24.3%; proportion of triple therapy: 54.6% versus 16.3%) and 12 months following the CV event (proportion of dual therapy: 31.7% versus 27.4%; proportion of triple therapy: 53.4% versus 21.1%). Those with a preceding exacerbation also experienced higher rates of hospitalisations, emergency department admissions and general practitioner and specialist physician visits in both the 12 months prior to and following the index event. Discussion: Patients whose index events were preceded versus not preceded by an exacerbation received more treatment regimens and classes of COPD therapy but still incurred more HCRU. Despite the greater healthcare contacts, there remained large treatment gaps in this high-risk population.